Volastra Therapeutics
Volastra is a clinical-stage biotech developing CIN-targeting oncology drugs for patients with difficult-to-treat cancers.
- 49
- New York, NY, USUnited States
Volastra is a clinical-stage biotech developing CIN-targeting oncology drugs for patients with difficult-to-treat cancers.
volastratx.comCrawled Oct 15, 2026
Dr. Compton is the dean of the Geisel School of Medicine at Dartmouth College
Dr. Vousden is chief scientist at Cancer Research UK (CRUK) and group leader at the Francis Crick Institute in London.
Dr. Cantley is a co-founder of Volastra and a world-renowned biologist and biochemist.
Dr. Elemento is a distinguished researcher developing new methodologies for the prevention, diagnosis, and treatment of cancer
CONTACT Volastra Therapeutics, Inc. 1361 Amsterdam Ave Suite 520 New York, NY 10027 General inquiries:
Volastra Therapeutics is a biotechnology company based in West Harlem in New York City.
Volastra Therapeutics, Inc. acknowledges concerns about how information about people is used and shared and says it appreciates their trust.
Volastra Therapeutics identifies **p16 expression**—a marker of Rb pathway inactivation—as a potential predictive biomarker for its **KIF18A inhibitor** program. The data, presented at **AACR 2026**, supports a pan-cancer development strategy targeting Rb pathway-driven tumors. The company defines a biomarker-driven approach to refine patient selection for KIF18A inhibition therapies.
Apr 2026VolastraNews article
Volastra Therapeutics names **Timothy Bowler, M.D., Ph.D.** as its new **Chief Medical Officer**. The clinical-stage biotech company develops **first-in-class therapies targeting chromosomal instability (CIN) in cancer**, with a focus on its **lead KIF18A inhibitor (KIF18Ai)**. Recent clinical data supports expansion of its development program, alongside advancements across its broader pipeline.
Jan 2026VolastraNews article
Volastra presents early results from its Phase I/II trial of the oral KIF18A inhibitor **VLS-1488**, showing tumor reduction in **7 of 17 heavily pre-treated patients with advanced ovarian cancer**. The findings will be shared at the **2025 ASCO Annual Meeting**. The drug targets KIF18A, a protein linked to cancer cell division.
May 2025VolastraNews article
Volastra Therapeutics begins dosing the first patient in a Phase Ib clinical trial of **sovilnesib**, its KIF18A inhibitor targeting cancers with high chromosomal instability. The trial marks progress for the company’s lead oncology asset, designed to address aggressive tumor types driven by genomic instability. Sovilnesib is one of two clinical-stage KIF18A inhibitors in Volastra’s pipeline.
Apr 2024VolastraNews article